Filtros de búsqueda

Lista de obras de

A monocentric phase I study of vemurafenib plus cobimetinib plus PEG-interferon (VEMUPLINT) in advanced melanoma patients harboring the V600BRAF mutation

scientific article published on 06 January 2021

Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy.

artículo científico publicado en 2014

Abstract 4017: Anti-tumor activity of a BRAF inhibitor and IFNα combination in BRAF mutant melanoma

artículo científico publicado en 2016

Adjuvant treatment of malignant melanoma: where are we?

artículo científico publicado en 2005

Analysis of T and NK cells immune response in Ipilimumab treated Melanoma patients.

artículo científico publicado en 2015

Anti-PD-1 and PD-L1 antibodies in metastatic melanoma

artículo científico publicado en 2017

Anti-PD1 and anti-PD-L1 in the treatment of metastatic melanoma.

artículo científico publicado en 2015

Antitumor Activity of BRAF Inhibitor and IFNα Combination in BRAF-Mutant Melanoma

artículo científico publicado en 2016

Assessing a novel immuno-oncology-based combination therapy: Ipilimumab plus electrochemotherapy

artículo científico publicado en 2015

Association of CTLA-4 Gene Variants with Response to Therapy and Long-term Survival in Metastatic Melanoma Patients Treated with Ipilimumab: An Italian Melanoma Intergroup Study.

artículo científico publicado en 2017

Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab

artículo científico publicado en 2016

Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab

CTLA-4 gene variant -1661A>G may predict the onset of endocrine adverse events in metastatic melanoma patients treated with ipilimumab

article

Clinical Experiences With Anti-CD137 and Anti-PD1 Therapeutic Antibodies ⬇️

artículo científico publicado el 1 de octubre de 2010

Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort

artículo científico publicado en 2014

Clinicopathologic features and surgical management of primary umbilical melanoma: a case series.

artículo científico publicado en 2015

Combination Treatment of Patients with BRAF-Mutant Melanoma: A New Standard of Care

artículo científico publicado en 2017

Combination therapy with ipilimumab and electrochemotherapy: preliminary efficacy results and correlation with immunological parameters.

artículo científico publicado en 2014

Combined vemurafenib and fotemustine in patients with BRAFV600 melanoma progressing on vemurafenib

artículo científico publicado en 2016

Complete response to nivolumab monotherapy in a treatment-naive, BRAF wild-type patient with advanced mucosal melanoma and elevated lactate dehydrogenase: a case report from a phase III trial

artículo científico publicado en 2016

Computer-aided diagnosis of melanocytic lesions.

artículo científico publicado en 2005

Correlation between BRAF mutational status and clinical response to pembrolizumab in advanced melanoma patients

artículo científico publicado en 2015

Correlation between immune-related adverse events and response to pembrolizumab in advanced melanoma patients.

artículo científico publicado en 2015

Correlation between previous treatment with BRAF inhibitors and clinical response to pembrolizumab in patients with advanced melanoma

artículo científico publicado en 2017

Corrigendum: Association of CTLA-4 Gene Variants with Response to Therapy and Long-term Survival in Metastatic Melanoma Patients Treated with Ipilimumab: An Italian Melanoma Intergroup Study. ⬇️

artículo científico publicado en 2018

Do BRAF inhibitors select for populations with different disease progression kinetics?

artículo científico publicado en 2013

Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases

artículo científico publicado en 2014

Efficacy of radiotherapy in patients on progression after treatment with ipilimumab 3 mg/kg.

artículo científico publicado en 2014

Electrochemotherapy efficacy evaluation for treatment of locally advanced stage III cutaneous squamous cell carcinoma: a 22-cases retrospective analysis.

artículo científico publicado en 2017

Electrochemotherapy in melanoma patients: a single institution experience

artículo científico publicado en 2015

Erratum to: Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma

scholarly article published in Cancer Immunology, Immunotherapy

Expression of CXCR4 Predicts Poor Prognosis in Patients with Malignant Melanoma

artículo científico publicado en 2005

FKBP51s signature in peripheral blood mononuclear cells of melanoma patients as a possible predictive factor for immunotherapy.

artículo científico publicado en 2017

Factors predicting the occurrence of germline mutations in candidate genes among patients with cutaneous malignant melanoma from South Italy

artículo científico publicado en 2006

Gemcitabine versus bacille Calmette-Guérin after initial bacille Calmette-Guérin failure in non-muscle-invasive bladder cancer: a multicenter prospective randomized trial

artículo científico publicado en 2010

High expression of a spliced variant of FKBP51 in peripheral blood mononuclear cells of melanoma patients may be related to PDL-1 on tumour and predictive of response to Ipilimumab

Human melanoma metastases express functional CXCR4.

artículo científico publicado en 2006

IL-15, TIM-3 and NK cells subsets predict responsiveness to anti-CTLA-4 treatment in melanoma patients

artículo científico publicado en 2016

Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma

article

Immunomodulating antibodies in the treatment of metastatic melanoma: the experience with anti-CTLA-4, anti-CD137, and anti-PD1.

artículo científico

Immunomodulatory pathways regulate expression of a spliced FKBP51 isoform in lymphocytes of melanoma patients.

artículo científico publicado en 2015

Immunotherapy Bridge 2017 and Melanoma Bridge 2017: meeting abstracts

artículo científico publicado en 2018

Immunotherapy in metastatic melanoma: a novel scenario of new toxicities and their management

artículo científico publicado en 2019

Impact of COVID-19 outbreak on cancer immunotherapy in Italy: a survey of young oncologists

scientific article published on 01 October 2020

Interferon alpha for the adjuvant treatment of melanoma: review of international literature and practical recommendations from an expert panel on the use of interferon

artículo científico publicado en 2013

Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial

artículo científico publicado en 2012

Long-lasting response to electrochemotherapy in melanoma patients with cutaneous metastasis

artículo científico publicado en 2013

Long-term response after electrochemotherapy in patients with relapsed or refractory cutaneous melanoma.

artículo científico publicado en 2014

Low-dose temozolomide before dendritic-cell vaccination reduces (specifically) CD4+CD25++Foxp3+ regulatory T-cells in advanced melanoma patients

artículo científico publicado en 2013

MEK Inhibitors in the Treatment of Metastatic Melanoma and Solid Tumors

artículo científico

MISIPI study: Melanoma ImmunoScore evaluation in patients treated with IPIlimumab.

artículo científico publicado en 2014

Marker utility for combination therapy

artículo científico

Neoplastic leptomeningitis presenting in a melanoma patient treated with dabrafenib (a V600EBRAF inhibitor): a case report

artículo científico publicado en 2012

Nevoid melanoma of the vagina: report of one case diagnosed on thin layer cytological preparations

artículo científico publicado en 2007

Nivolumab for the treatment of small cell lung cancer

scientific article published on 29 October 2019

Novel mechanisms and therapeutic approaches in melanoma: targeting the MAPK pathway

artículo científico publicado en 2015

PD-L1 expression with immune-infiltrate evaluation and outcome prediction in melanoma patients treated with ipilimumab

artículo científico publicado en 2018

PD-L1 inhibitors in the pipeline: Promise and progress.

artículo científico publicado en 2017

Pegylated arginine deiminase treatment of patients with metastatic melanoma: results from phase I and II studies

artículo científico publicado en 2005

Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma

artículo científico publicado en 2013

Phase III randomized study of fotemustine and dacarbazine versus dacarbazine with or without interferon-α in advanced malignant melanoma

artículo científico publicado en 2013

Proteomic test for anti-PD-1 checkpoint blockade treatment of metastatic melanoma with and without BRAF mutations

artículo científico publicado en 2019

Regulatory T cell frequency in patients with melanoma with different disease stage and course, and modulating effects of high-dose interferon-alpha 2b treatment

artículo científico publicado en 2010

Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use.

artículo científico publicado en 2012

Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian cohort of the ipilimumab expanded access program

artículo científico publicado en 2014

Serial detection of circulating tumour cells by reverse transcriptase-polymerase chain reaction assays is a marker for poor outcome in patients with malignant melanoma

artículo científico publicado en 2006

Serious haematological toxicity during and after ipilimumab treatment: a case series.

artículo científico publicado en 2014

Soluble CTLA-4 as a favorable predictive biomarker in metastatic melanoma patients treated with ipilimumab: an Italian melanoma intergroup study

article

Soluble interleukin-2 receptor in stage I–III melanoma

scientific article published on 01 February 2006

Systemic short chain fatty acids limit antitumor effect of CTLA-4 blockade in hosts with cancer

artículo científico publicado en 2020

Systems biology analysis of immune signaling in peripheral blood mononuclear cells (PBMC) of melanoma patients receiving ipilimumab; basis for clinical response biomarker identification ⬇️

artículo científico publicado en 2013

Systems biology analysis of immune signaling in peripheral blood mononuclear cells (PBMC) of melanoma patients receiving ipilimumab; basis for response biomarker identification.

artículo científico publicado en 2014

Temozolomide and cisplatin in avdanced malignant melanoma.

artículo científico publicado en 2005

The abscopal effect: efficacy of radiotherapy in patients on progression after treatment with ipilimumab 3 mg/kg

artículo científico publicado en 2013

The role of BRAF V600 mutation in melanoma

artículo científico publicado en 2012

The role of MEK inhibitors in the treatment of metastatic melanoma

artículo científico

The role of spectrophotometry in the diagnosis of melanoma

artículo científico publicado en 2010

The use of interferon in melanoma patients: a systematic review

artículo científico publicado en 2014

Update on PEG-interferon α-2b as adjuvant therapy in melanoma

artículo científico

Vemurafenib beyond progression in a patient with metastatic melanoma: a case report

artículo científico publicado en 2015

Vemurafenib in BRAFV600 mutated metastatic melanoma: a subanalysis of the Italian population of a global safety study.

artículo científico publicado en 2015

Vemurafenib plus cobimetinib in the treatment of mutated metastatic melanoma: the CoBRIM trial.

artículo científico publicado en 2015

[Cutaneous squamous cell carcinoma: immunotherapy for locally advanced and metastatic disease]

scientific article published on 01 July 2020

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda